Deep Proteomics of Normal Human Ovarian Surface Epithelium and Fallopian Tube Epi

正常人卵巢表面上皮和输卵管上皮的深层蛋白质组学

• 批准号: 8790827
• 负责人: Karin D Rodland
• 金额: $ 6.71万
• 依托单位: BATTELLE PACIFIC NORTHWEST LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-26 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8790827
• 关键词: Adenocarcinoma; BRCA1 gene; BRCA2 gene; Biological Assay; Biological Markers; Biometry; Cancer Biology; Cancer Death Rates; Cessation of life; Clinical; Clinical Oncology; Clinical Research; Collaborations; Complement; Data; Databases; Development; Diagnostic; Early Diagnosis; Epithelium; Fallopian Tube Diseases; Genome; Genomics; Genotype; Glial Fibrillary Acidic Protein; Glioblastoma; Gynecologic Surgical Procedures; Histocompatibility Testing; Human; Instruction; Lesion; Link; Malignant Neoplasms; Malignant neoplasm of ovary; Mammalian Oviducts; Measurement; Methods; Modeling; Molecular; Mollies; Mutation; Neurons; Normal tissue morphology; Outcome; Ovarian; Ovarian Serous Adenocarcinoma; Pathway interactions; Patients; Performance; Phenotype; Plasma; Post-Translational Protein Processing; Proteins; Proteome; Proteomics; Qualifying; RNA Splicing; Sampling; Serous; Serous Cystadenocarcinoma; Serum; Set protein; Source; Specimen; Surface; System; Systems Biology; Technology; Testing; The Cancer Genome Atlas; Tissues; Validation; Variant; Weight; Woman; Work; base; candidate marker; candidate selection; carcinogenesis; cell type; improved; mortality; neoplastic; nestin protein; oncology; outcome forecast; patient population; prospective; protein expression; screening; success; therapeutic target; tumor

DESCRIPTION (provided by applicant): The Overall Objective of the PNNL Clinical Proteome Characterization Center (PCPCC) is to facilitate cancer biomarker development by linking the cancer genotype to the cancer phenotype using detailed comprehensive and quantitative characterization of cancer proteomes to complement the extensive genome-level characterization provided by The Cancer Genome Atlas (TCGA). The PCPCC will contribute to the success of the planned network of Protein Characterization Centers (PPCs) by utilizing robust and quantitative proteomics technologies and workflows, including simultaneous application of state-of-the-art validated platforms and advanced developmental platforms, for systematic discovery and verification of protein biomarkers that can be qualified in clinical studies, using the cancer specimens and associated data provided by the CPTC. The Discovery Unit will make measurements providing a comprehensive and quantitative characterization of the cancer proteomes that provides Information including protein abundances, splicing variants, mutations, and posttranslational modifications to complement the genomic characterization for CPTC-supplied biospecimens. The extensive database of genomic information on these samples will be integrated with the quantitative proteomic measurements made by the PCPCC, other available proteomics Information (e.g., from other PCC's), and a systems-level analysis of tumor-specific pathways to produce a prioritized list of highly credentialed candidates based on a weighted integration of multiple sources of Information, including clinical oncology and cancer biology. The Verification Unit will systemically develop and apply multiplexed verification assays directed at specific protein targets as identified and selected by the Biomarker Candidate Selection Subcommittee. The PCPCC will develop sensitive, selective, quantitative assays for a minimum of 100 protein targets per year and apply ultra-sensitive assays to biometric verification with a throughput of at least 500 plasma (or serum) samples per year, for a total of at least 2500 samples. Additionally, as in the Discovery efforts, measurements with the best available validated platform will be augmented by measurements with a developmental high performance platform for the same samples (for an overall total of at least 1000 samples per year, and >5000 total) to provide quantitative measurements for low-abundance otherwise undetectable candidates. As part of a consortium of PCC's, the PCPCC will also work to advance the efforts of others based upon e.g. the cancer tumor proteomics data generated, as well as subsequent biomarker clinical qualification and validation efforts.

描述（由申请人提供）：PNNL临床蛋白质组表征中心（PCPCC）的总体目标是通过使用癌症蛋白质组的详细全面和定量表征将癌症基因型与癌症表型联系起来，以补充癌症基因组图谱（TCGA）提供的广泛基因组水平表征，从而促进癌症生物标志物的开发。PCPCC将通过利用强大的定量蛋白质组学技术和工作流程，包括同时应用最先进的验证平台和先进的开发平台，为计划中的蛋白质表征中心（PPC）网络的成功做出贡献。发现单位将进行测量，提供癌症蛋白质组的全面和定量表征，提供包括蛋白质丰度、剪接变体、突变和翻译后修饰的信息，以补充CPTC提供的生物标本的基因组表征。这些样本的基因组信息的广泛数据库将与PCPCC进行的定量蛋白质组学测量、其他可用的蛋白质组学信息（例如，从其他PCC的），和肿瘤特异性途径的系统级分析，以产生基于多个信息源（包括临床肿瘤学和癌症生物学）的加权整合的高度可信的候选者的优先列表。核查股将系统地开发和应用针对生物标志物候选选择小组委员会确定和选择的特定蛋白质靶点的多重核查测定法。PCPCC将为每年至少100个蛋白质靶点开发灵敏、选择性、定量检测，并将超灵敏检测应用于生物特征验证，每年至少处理500个血浆（或血清）样本，总计至少2500个样本。此外，与Discovery工作一样，使用最佳可用验证平台进行的测量将通过使用开发的高性能平台对相同样品进行测量来增强（每年总计至少1000个样品，总计>5000个），以提供低丰度的定量测量，否则无法检测到候选物。作为PCC联盟的一部分，PCPCC还将致力于推进其他人的工作，例如基于所产生的癌症肿瘤蛋白质组学数据，以及随后的生物标志物临床鉴定和验证工作。